Mechanism of potentiation of antithrombin III [AT-III] inhibition by sulfated xylans
- PMID: 2442830
- DOI: 10.1016/0049-3848(87)90148-4
Mechanism of potentiation of antithrombin III [AT-III] inhibition by sulfated xylans
Abstract
Anticoagulant properties of three sulfated compounds prepared from xylans isolated from corn cobs, larchwood and oatspelts were compared with heparin and sodium pentosan polysulfate (SP-54) by studying their effects on activated partial thromboplastin time (APTT), prothrombin time (PT) and thrombin time (TT) using pooled normal human plasma. These compounds were more effective than SP-54 in delaying coagulation by all the three procedures while oatspelts xylan sulfate was as effective as heparin in inhibiting APTT and PT and more effective than heparin in inhibiting TT on a molar basis. The sulfated xylans were more effective than heparin or SP-54 in potentiating the AT-III inhibition of amidolysis of H-D-Phe-Pip-Arg-pNa (S-2238) by thrombin (IIa) or amidolysis of Bz-Ile-Glu-Gly-Arg-pNa (S-2222) by Xa. Study of the high affinity binding of the xylan sulfates to AT-III-Sepharose column showed that the amount of the xylan sulfate recovered in the eluates from this peak was greatly increased with an increase in molecular weight (MW). A buffered mixture of IIa, AT-III and dansylarginine N-(3-ethyl-1,5-pentanediyl) amide (DAPA) was used to study the inactivation of IIa by AT-III. Larchwood xylan sulfate (2-10 micrograms) was found to accelerate this inactivation which was neutralized by human platelet factor 4 (PF4). The results also suggested an interaction between larchwood xylan sulfate and IIa which may potentiate an interaction between AT-III and IIa.
Similar articles
-
Effect of sulfated xylans during the interaction of [125I]-thrombin with antithrombin III or heparin cofactor II of human plasma.Eur J Drug Metab Pharmacokinet. 1995 Jan-Mar;20(1):73-7. doi: 10.1007/BF03192291. Eur J Drug Metab Pharmacokinet. 1995. PMID: 7588997
-
Mechanism of potentiation of antithrombin III and heparin cofactor II inhibition by sulfated xylans.Thromb Res. 1990 May 15;58(4):367-81. doi: 10.1016/0049-3848(90)90208-t. Thromb Res. 1990. PMID: 1972302
-
Isolation and anticoagulant properties of a new sulfated xylan: comparison with heparin and a sodium pentosan polysulfate (SP-54).Thromb Res. 1983 Jun 15;30(6):573-8. doi: 10.1016/0049-3848(83)90265-7. Thromb Res. 1983. PMID: 6193601
-
Rationale behind the development of low molecular weight heparin derivatives.Semin Thromb Hemost. 1985 Jan;11(1):13-6. doi: 10.1055/s-2007-1004352. Semin Thromb Hemost. 1985. PMID: 2579436 Review.
-
Molecular weight of heparin versus biologic activity. Some additional considerations.Semin Thromb Hemost. 1985 Jan;11(1):29-33. doi: 10.1055/s-2007-1004355. Semin Thromb Hemost. 1985. PMID: 2579437 Review. No abstract available.
Cited by
-
Effect of sulfated xylans during the interaction of [125I]-thrombin with antithrombin III or heparin cofactor II of human plasma.Eur J Drug Metab Pharmacokinet. 1995 Jan-Mar;20(1):73-7. doi: 10.1007/BF03192291. Eur J Drug Metab Pharmacokinet. 1995. PMID: 7588997
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous